Hormonal
Administration of 4 g daily of omega-3 carboxylic acids (Epanova) to statin-treated high-risk patients with hypertriglyceridemia and low HDL-C reduces triglycerides by 26-31% and non-HDL-C, but its impact on reducing cardiovascular events is currently unknown and being tested in the STRENGTH trial.
If you are on a statin and still have high triglycerides and low HDL, your cardiovascular risk remains elevated. This trial investigates whether adding 4 grams of a specific prescription omega-3 (Epanova) daily, on top of your statin, can lower those lipids and prevent heart events. While it reliably lowers triglycerides, whether this translates to fewer heart attacks or strokes is still being determined by the STRENGTH trial results.
STRENGTH will examine whether Epanova 4 g daily reduces the rate of cardiovascular events in statin-treated patients with hypertriglyceridemia and low levels of HDL-C at high risk for developing cardiovascular events.
Why this rating
The paper describes a trial design and prior observational/subgroup data; the primary outcome (CV events) has not yet been reported.
Source
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al. · Clinical Cardiology · 2018
DOI 10.1002/clc.23055
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →